Also expressed in tumors harboring ERG rearrangements: 50% of prostatic adenocarcinomas and 5% of Ewing sarcomas

Terminology

V-ets erythroblastosis virus E26 oncogene homolog

ERG3

p55

Transcriptional regulator ERG (transforming protein ERG)

Interpretation

Nuclear staining

Uses by pathologists

Currently one of the best available markers of endothelial differentiation, including vascular neoplasms such as: hemangioma, hemangioendothelioma, angiosarcoma and Kaposi sarcoma (Am J Surg Pathol 2011;35:432)

Nuclear expression can assess the presence of TMPRSS2-ERG or SLC45A3-ERG fusions in prostatic adenocarcinomas; however, since only about 40 - 50% of these tumors harbor ERG rearrangement, and as high grade prostatic intraepithelial neoplasia or other mimics can also be positive, this marker is rarely used for the diagnosis of prostate adenocarcinoma in routine clinical practice, providing useful information (beyond other stains) in only 29% of cases (Am J Surg Pathol 2011;35:1014, Adv Anat Pathol 2018;25:387, Am J Surg Pathol 2014;38:1007)

This website is intended for pathologists and laboratory personnel, who understand that medical information is imperfect and must be interpreted using reasonable medical judgment. We are unable to respond to patient inquiries.